Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: Are conclusive results available?

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 1, 2009, Pages 76-91

  Pereira, Carina ^a,b   Medeiros, Rui M ^a   Dinis Ribeiro, Mário J ^a,b,c  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b Res Dept of the Port League Against Cancer Liga Portuguesa Contra O Cancro Nucleo Reg Do Norte   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Colon cancer; Cyclooxygenases; Gastric cancer; Meta analysis; Polymorphisms

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTAGLANDIN SYNTHASE;

ARTICLE; CANCER RISK; CARCINOGENESIS; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; ENZYME POLYMORPHISM; GENE FREQUENCY; HETEROZYGOTE; HUMAN; OUTCOME ASSESSMENT; PRECANCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CARCINOMA;

CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GENE FREQUENCY; HUMANS; POLYMORPHISM, GENETIC; PRECANCEROUS CONDITIONS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 58149215969     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32830ce7ba     Document Type: Article

References (83)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48:3554-3560.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-767.
4. Hamilton SR. The adenoma-adenocarcinoma sequence in the large bowel: variations on a theme. J Cell Biochem Suppl 1992; 16G:41-46.
5. Yaghoobi M, Rakhshani N, Sadr F, Bijarchi R, Joshaghani Y, Mohammadkhani A, et al. Hereditary risk factors for the development of gastric cancer in younger patients. BMC Gastroenterol 2004; 4:28.
6. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12:354-362.
7. American Cancer Society. Colorectal Cancer Facts & Figures Special Edition 2005. Atlanta: American Cancer Society; 2007.
8. Berlau J, Glei M, Pool-Zobel BL. Colon cancer risk factors from nutrition. Anal Bioanal Chem 2004; 378:737-743.
9. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-867.
10. Marx J. Cancer research. Inflammation and cancer: the link grows stronger. Science 2004; 306:966-968.
11. Macarthur M, Hold GL, El-Omar EM. Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2004; 286:515-520.
12. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6:130-140.
13. Thun MJ, Henley SJ, Gansler T. Inflammation and cancer: an epidemiological perspective. Novartis Found Symp 2004; 256:6-21.
14. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003; 95:1784-1791.
15. Jolly K, Cheng KK, Langman MJ. NSAIDs and gastrointestinal cancer prevention. Drugs 2002; 62:945-956.
16. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232-235.
17. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104:2S-8S.
18. Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biol 2004; 5:241.
19. DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12:1063-1073.
20. Bakhle YS. COX-2 and cancer: a new approach to an old problem. Br J Pharmacol 2001; 134:1137-1150.
21. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190:279-286.
22. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol 2006; 12:1336-1345.
23. van Rees BP, Ristimaki A. Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract. Scand J Gastroenterol 2001; 36:897-903.
24. Wu AW, Gu J, Ji JF, Li ZF, Xu GW. Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. World J Gastroenterol 2003; 9:1990-1994.
25. Yu LZ, Gao HJ, Bai JF, Sun G, Zhao HL, Sun L, et al. Expression of COX-2 proteins in gastric mucosal lesions. World J Gastroenterol 2004; 10:292-294.
26. Garcea G, Sharma RA, Dennison A, Steward WP, Gescher A, Berry DP. Molecular biomarkers of colorectal carcinogenesis and their role in surveillance and early intervention. Eur J Cancer 2003; 39:1041-1052.
27. Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005; 129:565-576.
28. Guo Y, Zhang X, Tan W, Miao X, Sun T, Zhao D, et al. Platelet 12-Lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphism. Pharmacogenet Genomics 2007; 17:197-205.
29. Moons LM, Kuipers EJ, Rygiel AM, Groothuismink AZ, Geldof H, Bode WA, et al. COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. Am J Gastroenterol 2007; 102:2373-2379.
30. Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnston BT, Murray LJ, et al. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism and risk of reflux esophagitis, Barret's esophagus, and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008; 17:727-731.
31. Zhang XM, Miao XP, Tan W, Sun T, Guo YL, Zhao D, et al. [Genetic polymorphisms in the promoter region of cyclooxygenase-2 and their association with risk of gastric cancer]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2006; 28:119-123.
32. Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E. Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis 2005; 26:449-457.
33. Zhang W, Gordon M, Press OA, Rhodes K, Vallböhmer D, Yang DY, et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 2006; 16:475-483.
34. Gordon MA, Gil J, Lu B, Zhang W, Yang D, Yun J, et al. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 2006; 7:67-88.
35. Pereira C, Sousa H, Ferreira P, Fragoso M, Moreira-Dias L, Lopes C, et al. -765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J Gastroenterol 2006; 12:5473-5478.
36. Liu F, Pan K, Zhang X, Zhang Y, Zhang L, Ma J, et al. Genetic variants in cyclooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology 2006; 130:1975-1984.
37. Ulrich CM, Bigler J, Sparks R, Whitton J, Sibert JG, Goode EL, et al. Polymorphisms in PTGS1 (= COX-1) and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2004; 13:889-893.
38. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, et al. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005; 14:616-619.
39. Ali IU, Luke BT, Dean M, Greenwald P. Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br J Cancer 2005; 93:953-959.
40. Siezen CL, Tijhuis MJ, Kram NR, van Soest EM, de Jong DJ, Fodde R, et al. Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta. Pharmacogenet Genomics 2006; 16:43-50.
41. Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2006; 15:1126-1131.
42. Lin HJ, Lakkides KM, Keku TO, Reddy ST, Louie AD, Kau IH, et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2002; 11:1305-1315.
43. Hamajima N, Takezaki T, Matsuo K, Saito T, Inoue M, Hirai T, et al. Genotype Frequencies of Cyclooxygenease 2 (COX2) Rare Polymorphisms for Japanese with and without Colorectal Cancer. Asian Pac J Cancer Prev 2001; 2:57-62.
44. Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T, et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 2007; 28:1197-1201.
45. Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, et al. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer 2004; 91:339-343.
46. Landi S, Gemignani F, Bottari F, Gioia-Patricola L, Guino E, Cambray M, et al. Polymorphisms within inflammatory genes and colorectal cancer. J Negat Results Biomed 2006; 5:15.
47. Goodman JE, Bowman ED, Chanock SJ, Albert AJ, Harris CC. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 2004; 25:2467-2472.
48. Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, van DM, van Kranen HJ. Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer 2006; 119:297-303.
49. Koh WP, Yuan JM, van den BD, Lee HP, Yu MC. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br J Cancer 2004; 90:1760-1764.
50. Sansbury LB, Millikan RC, Schroeder JC, North KE, Moorman PG, Keku TO, et al. COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States). Cancer Causes Control 2006; 17:257-266.
51. Xing LL, Wang ZN, Jiang L, Zhang Y, Xu YY, Luo Y, et al. Cyclooxygenase 2 polymorphism and colorectal cancer: -765G > C variant modifies risk associated with smoking and body mass index. World J Gastroenterol 2008; 14:1785-1789.
52. Saxena A, Prasad KN, Ghoshal UC, Bhagat MR, Krishnani N, Husain N. Polymorphism of -765G > C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H. pylori infection: a study from northern India. World J Gastroenterol 2008; 14:1498-1503.
53. Canzian F, Franceschi S, Plummer M, van Doorn LJ, Lu Y, Gioia-Patricola L, et al. Genetic polymorphisms in mediators of inflammation and gastric precancerous lesions. Eur J Cancer Prev 2008; 17:178-183.
54. Ueda N, Maehara Y, Tajima O, Tabata S, Wakabashi K, Kono S. Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: the Self Defense Forces Health Study. Cancer Sci 2008; 99:576-781.
55. Hou L, Grillo P, Zhu ZZ, Lissowska J Yeager M, Zatonski W, et al. COX1 and COX2 polymorphisms and gastric cancer risk in a Polish population. Anticancer Res 2007; 27:4243-4247.
56. Poole EM, Bigler J, Whitton J, Sibert JG, Kulmacz PJ, Potter JD, et al. Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps. Carcinogenesis 2007; 28:1259-1263.
57. Sitarz R, Leguit RJ, de Leng WW, Polak M, Morsink FM, Bakker O, et al. The COX-2 promoter polymorphism in -765G > C is associated with early-onset, conventional and stump gastric cancers. Mod Pathol 2008; 21:685-690.
58. Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ, Houlston RS, et al. Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal recurrence in the context of a randomized aspirin intervention trial. Int J Cancer 2007; 121:2001-2004.
59. Saukken K, Nieminen O, van Rees B, Vilkki S, Härkönem M, Juhola M, et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001; 7:1923-1931.
60. Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, Duffy D, et al. Systematic review and meta-analysis of the association between (beta)2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 2005; 162:201-211.
61. STROBE statement: Checklist of essential items Version 3 (Sept 2005).
62. den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet 2001; 109:121-124.
63. Review Manager (RevMan) [computer program]. Version 4.2. for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
64. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
65. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005; 28:123-137.
66. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. Br Med J 2001; 323:101-105.
67. Knudsen LE, Loft SH, Autrup H. Risk assessment: the importance of genetic polymorphisms in man. Mutat Res 2001; 482:83-88.
68. Ulrich CM, Bigler J, Sibert J, Greene EA, Sparks R, Carlson CS, et al. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 2002; 20:409-410.
69. Shi J, Misso NL, Duffy DL, Bradley B, Beard R, Thompson PJ, et al. Cyclooxygenase-1 gene polymorphisms in patients with different asthma phenotypes and atopy. Eur Respir J 2005; 26:249-256.
70. Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994; 367:243-249.
71. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: the atherosclerosis risk in communities (ARIC) study. Clin Pharmacol Ther 2008; 83:52-60.
72. Ahmed FE. Gene-gene, gene environment & multiple interactions in colorectal cancer. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2006; 24:1-101.
73. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002; 22:1631-1636.
74. Szczeklik W, Sanak M, Szczeklik A. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 2004; 114:248-253.
75. Kanaoka S, Takai T, Yoshida K. Cyclooxygenase-2 and tumor biology. Adv Clin Chem 2007; 43:59-78.
76. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348:891-899.
77. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348:883-890.
78. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. J Am Med Assoc 2005; 294:914-923.
79. Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 2001; 12:88-93.
80. Dixon DA. Regulation of COX-2 expression in human cancers. Prog Exp Tumor Res 2003; 37:52-71.
81. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J Biol Chem 2000; 275:11750- 11757.
82. Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 2004; 25:229-235.
83. Attia J, Thakkinstian A, D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol 2003; 56:297-303.